Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Institutional Innovation in Devices

This article was originally published in Start Up

Executive Summary

These days, medtech investors need to be much more selective about how they spend their capital. In pursuit of steady streams of early-stage opportunities with a high likelihood of success, VCs are establishing closer ties with entprepreneurs and executives they feel can do it again.

You may also be interested in...



Toward Spectacle-Free Cataract Surgery

After a lull, or at least a single-minded focus on femtosecond lasers for a time, refractive surgery has gotten exciting again: the drive to spectacle-free outcomes for cataract patients (who have aged-out of their eligibility for other refractive procedures) is calling for solutions that offer precision and accuracy at every stage of treatment. Start-ups coming up with the solutions will be serving some gigantic markets.

Best of the Blog: Start-Up June 2008

Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In June and early July Windhover's editorial staff posted more than seventy articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included a discussion of biotech exit strategies and a peek at the results of a survey about the worth of advice from investment bankers. Here are a few of our favorite blog posts for stories not covered elsewhere in this month's START-UP.

Happy Return: QLT Bets Big on ForSight Plug

Publicly traded QLT Inc. is trying to capture lightning in a bottle; it has acquired the second company spawned by ForSight Labs, the incubator created by The Foundry. The still unnamed company has developed drug-eluting punctual plugs that QLT believes could challenge the $6 billion eye-drop industry.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel